Dignitana AB (publ.)
Dignitana AB (publ), a medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally. It offers DigniCap, a scalp cooling system used to reduce hair loss from chemotherapy treatments, as well as for patients receiving chemotherapy to treat other solid tumors. The company was incorporated in 2007 is headquarter… Read more
Dignitana AB (publ.) (DIZTF) - Net Assets
Latest net assets as of March 2025: $4.29 Million USD
Based on the latest financial reports, Dignitana AB (publ.) (DIZTF) has net assets worth $4.29 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.09 Million) and total liabilities ($24.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.29 Million |
| % of Total Assets | 14.76% |
| Annual Growth Rate | 3.73% |
| 5-Year Change | -90.84% |
| 10-Year Change | -82.56% |
| Growth Volatility | 74.65 |
Dignitana AB (publ.) - Net Assets Trend (2008–2024)
This chart illustrates how Dignitana AB (publ.)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dignitana AB (publ.) (2008–2024)
The table below shows the annual net assets of Dignitana AB (publ.) from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.11 Million | -2.06% |
| 2023-12-31 | $7.26 Million | -70.05% |
| 2022-12-31 | $24.25 Million | -22.24% |
| 2021-12-31 | $31.19 Million | -59.83% |
| 2020-12-31 | $77.64 Million | +40.89% |
| 2019-12-31 | $55.10 Million | +0.25% |
| 2018-12-31 | $54.97 Million | +7.47% |
| 2017-12-31 | $51.15 Million | -8.46% |
| 2016-12-31 | $55.87 Million | +36.98% |
| 2015-12-31 | $40.79 Million | +179.76% |
| 2014-12-31 | $14.58 Million | -48.18% |
| 2013-12-31 | $28.14 Million | +2.73% |
| 2012-12-31 | $27.39 Million | +193.85% |
| 2011-12-31 | $9.32 Million | -28.22% |
| 2010-12-31 | $12.98 Million | +75.13% |
| 2009-12-31 | $7.41 Million | +87.36% |
| 2008-12-31 | $3.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dignitana AB (publ.)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25096900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.05 Million | 113.21% |
| Other Components | $263.82 Million | 3708.53% |
| Total Equity | $7.11 Million | 100.00% |
Dignitana AB (publ.) Competitors by Market Cap
The table below lists competitors of Dignitana AB (publ.) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Biotechnology Assets S.A.
MC:BST
|
$8.44 Million |
|
Manaksia Limited
NSE:MANAKSIA
|
$8.44 Million |
|
Sino Logistics Corporation Public Company Limited
BK:SINO
|
$8.44 Million |
|
Knight Club Capital Asset Management PCL
BK:KCC
|
$8.44 Million |
|
HSS HIRE GROUP LS -01
F:HG3
|
$8.43 Million |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
$8.43 Million |
|
PSS EXOL SA D ZY 1
F:9B2
|
$8.43 Million |
|
Bioatla Inc
NASDAQ:BCAB
|
$8.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dignitana AB (publ.)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,264,000 to 7,114,000, a change of -150,000 (-2.1%).
- Net loss of 19,179,000 reduced equity.
- New share issuances of 13,564,000 increased equity.
- Other comprehensive income increased equity by 246,333,000.
- Other factors decreased equity by 240,868,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.18 Million | -269.6% |
| Share Issuances | $13.56 Million | +190.67% |
| Other Comprehensive Income | $246.33 Million | +3462.65% |
| Other Changes | $-240.87 Million | -3385.83% |
| Total Change | $- | -2.06% |
Book Value vs Market Value Analysis
This analysis compares Dignitana AB (publ.)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.25x to 1.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.69 | $0.17 | x |
| 2009-12-31 | $1.26 | $0.17 | x |
| 2010-12-31 | $1.00 | $0.17 | x |
| 2011-12-31 | $0.72 | $0.17 | x |
| 2012-12-31 | $1.66 | $0.17 | x |
| 2013-12-31 | $1.54 | $0.17 | x |
| 2014-12-31 | $0.81 | $0.17 | x |
| 2015-12-31 | $1.58 | $0.17 | x |
| 2016-12-31 | $1.81 | $0.17 | x |
| 2017-12-31 | $2.52 | $0.17 | x |
| 2018-12-31 | $1.36 | $0.17 | x |
| 2019-12-31 | $1.10 | $0.17 | x |
| 2020-12-31 | $1.41 | $0.17 | x |
| 2021-12-31 | $0.48 | $0.17 | x |
| 2022-12-31 | $0.37 | $0.17 | x |
| 2023-12-31 | $0.10 | $0.17 | x |
| 2024-12-31 | $0.09 | $0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dignitana AB (publ.) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -269.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.35%
- • Asset Turnover: 2.55x
- • Equity Multiplier: 4.96x
- Recent ROE (-269.60%) is below the historical average (-116.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -346.85% | -652.33% | 0.14x | 3.76x | $-14.12 Million |
| 2009 | -145.32% | -626.03% | 0.10x | 2.29x | $-11.52 Million |
| 2010 | -166.02% | -546.69% | 0.19x | 1.62x | $-22.85 Million |
| 2011 | -39.31% | -66.28% | 0.36x | 1.64x | $-4.60 Million |
| 2012 | -48.31% | -147.51% | 0.26x | 1.27x | $-15.97 Million |
| 2013 | -58.86% | -164.01% | 0.29x | 1.25x | $-19.37 Million |
| 2014 | -74.86% | -53.67% | 0.96x | 1.45x | $-12.37 Million |
| 2015 | -40.62% | -348.89% | 0.10x | 1.17x | $-20.65 Million |
| 2016 | -57.76% | -362.49% | 0.14x | 1.14x | $-37.86 Million |
| 2017 | -83.29% | -185.69% | 0.28x | 1.61x | $-47.71 Million |
| 2018 | -47.34% | -77.12% | 0.42x | 1.46x | $-31.52 Million |
| 2019 | -69.03% | -93.45% | 0.50x | 1.48x | $-43.55 Million |
| 2020 | -68.22% | -113.58% | 0.34x | 1.78x | $-60.73 Million |
| 2021 | -138.16% | -75.49% | 0.80x | 2.29x | $-46.20 Million |
| 2022 | -92.42% | -30.70% | 1.25x | 2.41x | $-24.84 Million |
| 2023 | -239.03% | -20.17% | 1.92x | 6.17x | $-18.09 Million |
| 2024 | -269.60% | -21.35% | 2.55x | 4.96x | $-19.89 Million |
Industry Comparison
This section compares Dignitana AB (publ.)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dignitana AB (publ.) (DIZTF) | $4.29 Million | -346.85% | 5.77x | $8.43 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |